Loading quotes...

Forecast

The analysts' average price target is €1,214.58 (+5.68%). The median is €1,237.21 (+7.65%).

Buy	33
Hold	9
Sell	3

News Go to news feed

Eli Lilly reaches new all-time high thanks to strong demand for tirzepatide products

Eli Lilly’s stock climbed to a new record, trading for the first time at $1,300 per share, driven by strong demand for the tirzepatide-based drugs Zepbound and Mounjaro. The two medicines generated about $15 billion in the second quarter; group revenues rose 48 percent overall to $23 billion. Investors are watching third-quarter figures expected on October 29, while Eli Lilly is simultaneously making acquisitions and expanding collaborations in AI and LNP areas, most recently with METiS TechBio. » More on deraktionaer.de
Eli Lilly receives EMA recommendation for weight-loss pill Foundayo

An EMA committee has recommended approval of Foundayo for weight control and for the treatment of type 2 diabetes in adults. The European Commission must still agree to the recommendation before Eli Lilly can market the drug in the EU. Foundayo would be, after Wegovy from Novo Nordisk, the second oral weight‑loss pill in the EU and increases competitive pressure on Novo, whose share price has fallen significantly from its peak. » More on manager-magazin.de
Eli Lilly ramps R&D and acquisitions to replace GLP-1 revenue before 2030s patent cliff

Eli Lilly, whose GLP-1 weight-loss and diabetes drugs generated 62% of trailing 12‑month revenue and helped push its market cap above $1 trillion, is spending heavily to diversify its pipeline before patents lapse in the 2030s. The company increased R&D to $13.3 billion in 2025 (and $7.3 billion in H1 2026) and has struck 31 deals this year, spending roughly $18 billion on acquisitions and licenses including Kelonia, Centessa and AtaiBeckley. Lilly is investing across oncology, neurology, sleep and psychedelics, and backing AI drug discovery with a $1 billion Nvidia partnership to seed next-generation blockbusters. CEO Dave Ricks says the moves aim to sustain growth rather than return capital if the GLP-1 franchise declines. » More on forbes.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Eli Lilly & Co has already paid €4.48 in dividends. The last payout was in September.

Financials

In the last quarter, Eli Lilly & Co had revenue of €20.13B and net profit of €6.22B

(EUR)	June 2026	YoY
Revenue	20.13B	52.50%
Gross profit	17.27B	55.24%
Net profit	6.22B	29.44%
EBITDA	11.38B	78.91%

Fundamentals

Metric	Value
Market capitalization	€1.07T
Number of shares	941.36M
52-week high/low	€1,184.07 - €725.59
Dividend yield	0.50%
Dividends TTM	€5.76
Beta	0.45
P/E ratio	42.60
PEG ratio	0.45
P/B ratio	33.54
P/S ratio	15.05

Company profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Name	Eli Lilly & Co
CEO	David A. Ricks
Headquarters	Indianapolis, in USA
Website	lilly.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	06/01/1972
Employees	50,000